REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2017

Mar 2, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2017-03-02

Reporting Person: Fenimore Christopher R. (VP, Controller)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1328	Indirect
Common Stock	2695	Indirect
Common Stock	4297	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Incentive Stock Option (right to buy)	$21.25	2019-12-18	Common Stock (1375)		Direct
Incentive Stock Option (right to buy)	$30.63	2020-12-14	Common Stock (4280)		Direct
Incentive Stock Option (right to buy)	$52.03	2021-12-16	Common Stock (2224)		Direct
Non-Qualified Stock Option (right to buy)	$52.03	2021-12-16	Common Stock (13776)		Direct
Non-Qualified Stock Option (right to buy)	$179.13	2022-12-14	Common Stock (23500)		Direct
Non-Qualified Stock Option (right to buy)	$270.43	2023-12-13	Common Stock (20000)		Direct
Non-Qualified Stock Option (right to buy)	$381.92	2026-12-16	Common Stock (12283)		Direct
Non-Qualified Stock Option (right to buy)	$399.66	2024-12-16	Common Stock (17000)		Direct
Non-Qualified Stock Option (right to buy)	$555.67	2025-12-16	Common Stock (14450)		Direct

Footnotes

F1: These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust.

F2: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

F3: The stock option award vests in four equal annual installments, commencing one year after the date of grant.